United Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $3.61, $0.89 better than the analyst estimate of $2.72. Revenue for the quarter came in at $356.3 million versus the consensus estimate of $344.33 million.

"I'm proud of the efforts of the entire United Therapeutics team to ensure continued access to our life-sustaining therapies during this unprecedented time," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. "We're excited that our supplemental new drug application to expand the potential Tyvaso® patient population with the INCREASE study results remains on track for a mid-year filing and, along with our partner DEKA, we're preparing for a July 2020 launch of our Remunity Pump."

Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, commented, "We're pleased with Remodulin®'s continued resilience in the face of generic competition and Orenitram's 18% year-over-year revenue growth, which we attribute to physician reception of the FREEDOM-EV data showing that Orenitram, when used in combination with an approved oral background therapy, delays disease progression and leads to improvement across key clinical parameters. We see these data, plus the recently announced publications demonstrating Orenitram's positive effect on hemodynamics, risk status, and PAH-related healthcare costs, as enhancing Orenitram's value proposition."

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.